To study the involvement of KRAS and BRAF mutations in anoikis resistance in colorectal carcinoma cells in vitro and to develop an in vitro model for multicellular clusters occurring in actual carcinomas in vivo that corresponds to anoikis resistance, we generated modified Caco-2 cell lines with KRAS G12V or BRAF V600E mutations. This evidence concerns the gene KRAS and carcinoma.